The ANDVA Advisor Blog, published by Carlson Caspers, focuses on legal issues related to pharmaceutical patent litigation, particularly involving the Hatch-Waxman Act and ANDA (Abbreviated New Drug Application) cases. It covers topics such as the tax treatment of litigation costs in ANDA cases, patent enablement and written description requirements under Section 112 of the Patent Act, challenges to patent listings in the FDA's Orange Book, and significant court decisions affecting patent validity and enforcement. The blog also discusses Supreme Court and Federal Circuit rulings impacting patent law, including enablement standards for genus claims and the implications for biosimilar and pharmaceutical companies.